Stock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns

Stock Track07-22

Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.

The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.

Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176509502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176509502","market":"us","top_or_hot":-1,"title":"Stock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns","media":"Stock Track","content":"<p>Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.</p><p>The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.</p><p>Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-22 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.</p><p>The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.</p><p>Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDY","symbol_name":"如瑞迪博士","start_time":0,"source_url":"","article_id":"1176509502","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176509502","pubTimestamp":1784727158,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDY":"如瑞迪博士"},"translate_title":"股票跟踪 | Dr Reddy's Laboratories 因盈利低迷和特朗普关税担忧暴跌 5.41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY":1},"content_text":"Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176509502","isCrawlerRequest":true}